Juno uses lethal neurotox lessons to guide Goldilocks formula for its next-gen CAR-T
WASHINGTON, DC — Neurotoxicity killed JCAR015 right along with 5 patients in the lead pivotal study, derailing Juno Therapeutics $JUNO and allowing first Novartis and then Gilead/Kite to surge way ahead with the first two approvals in the field. But Juno now plans to take what it’s learned from that lethal implosion and make over its next drug — JCAR017 — into what it promises will be a dramatically improved drug that can leapfrog the leaders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.